Survival rates according to barcelona clinic liver cancersub-staging system after transarterial embolization forintermediate hepatocellular carcinoma

• Published in: 世界肝病学杂志：英文版（电子版） no. 3; pp. 628 - 632
• Main Author: Leandro Armani Scaffaro Steffan Frosi Stella Mario Reis Alvares-Da-Silva Cleber Dario Pinto Kruel
• Format: Journal Article
• Language: English
• Published: 2015
• Subjects: Barcelona; cancer; carcinoma; clinicliver; embolization; Hepatocellular; Subclassification; Transarterial
• ISSN: 1948-5182; 1948-5182

AIM To investigate the survival rates after transarterialembolization （TAE）.METHODS： One hundred third six hepatocellularcarcinoma （HCC） patients [90 barcelona clinic livercancer （BCLC） B] were submitted to TAE betweenAugust 2008 and December 2013 in a single centerwere retrospectively studied. TAE was performed viasuperselective catheterization followed by embolizationwith polyvinyl alcohol or microspheres. The date of thefirst embolization until death or the last follow-up datewas used for the assessment of survival. The survivalrates were calculated using the Kaplan-Meier method,and the groups were compared using the log-rank test.RESULTS： The overall mean survival was 35.8 mo（95%CI： 25.1-52.0）. The survival rates of the BCLC Apatients （33.7%） were 98.9%, 79.0% and 58.0% at12, 24 and 36 mo, respectively, and the mean survivalwas 38.1 mo （95%CI： 27.5-52.0）. The survival rates ofthe BCLC B patients （66.2%） were 89.0%, 69.0% and49.5% at 12, 24 and 36 mo, respectively, and the meansurvival was 29.0 mo （95%CI： 17.2-34）. The survivalrates according to the BCLC B sub-staging showedsignificant differences between the groups, with meansurvival rates in the B1, B2, B3 and B4 groups of 33.5mo （95%CI： 32.8-34.3）, 28.6 mo （95%CI： 27.5-29.8）,19.0 mo （95%CI： 17.2-20.9） and 13 mo, respectively （P= 0.013）.CONCLUSION： The BCLC sub-staging systemcould add additional prognosis information for postembolizationsurvival rates in HCC patients.